Jotin Marango - 03 Jan 2023 Form 4 Insider Report for Ikena Oncology, Inc. (IKNA)

Role
CFO & Head of Corp. Dev.
Signature
/s/ Mark Manfredi, as Attorney-in-Fact for Jotin Marango
Issuer symbol
IKNA
Transactions as of
03 Jan 2023
Net transactions value
$0
Form type
4
Filing time
05 Jan 2023, 15:15:17 UTC
Previous filing
25 Apr 2022
Next filing
02 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKNA Stock Option (Right to Buy) Award $0 +105,000 $0.000000 105,000 03 Jan 2023 Common Stock 105,000 $2.62 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter.